Alector Inc (STU:0Z2)
€ 3.98 -0.02 (-0.5%) Market Cap: 391.41 Mil Enterprise Value: -93.80 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 62/100

Alector Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 04:55PM GMT
Release Date Price: €15.21 (+5.17%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So thanks for joining us. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Alector with me for the next session. Just before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk. So very happy to have with me Arnon Rosenthal, who is the CEO of Alector and Arnon I thought the best thing to do is maybe make sure your microphone is working. Your microphone is working fine.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Start off with your approach to neurodegeneration. I think it's a unique approach compared to some of the other approaches that people are taking. And I think that's a good segue to then walk through the pipeline?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot